BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Gets Price Target Reduction from Royal Bank Of Canada

BioMarin Pharmaceutical (NASDAQ:BMRN) had its target price trimmed by Royal Bank Of Canada from $62.00 to $60.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a sector perform rating on the biotechnology company’s stock.

A number of other equities research analysts also recently issued reports on BMRN. BMO Capital Markets reissued an “outperform” rating on shares of BioMarin Pharmaceutical in a research report on Wednesday, September 16th. Jefferies Financial Group upped their price target on BioMarin Pharmaceutical from $104.00 to $105.00 and gave the stock a “buy” rating in a research note on Monday, August 31st. Morgan Stanley cut their price objective on BioMarin Pharmaceutical from $124.00 to $122.00 and set an “overweight” rating on the stock in a report on Wednesday, October 21st. Raymond James Financial raised BioMarin Pharmaceutical from an “outperform” rating to a “strong-buy” rating and set a $109.00 price objective on the stock in a research note on Monday, October 12th. Finally, William Blair raised BioMarin Pharmaceutical to a “hold” rating in a research note on Wednesday, September 23rd. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $87.91.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $56.15 on Tuesday. The company has a market cap of $10.88 billion, a P/E ratio of 32.10, a P/E/G ratio of 0.68 and a beta of 0.21. The firm’s 50 day moving average is $59.87 and its two-hundred day moving average is $58.47. BioMarin Pharmaceutical has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The company has a quick ratio of 1.32, a current ratio of 2.44 and a debt-to-equity ratio of 0.56.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.28. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.02 billion. BioMarin Pharmaceutical had a negative net margin of 0.52% and a positive return on equity of 5.58%. The business’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.12 EPS. Analysts expect that BioMarin Pharmaceutical will post 2.49 EPS for the current year.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Maryland State Retirement & Pension System grew its stake in shares of BioMarin Pharmaceutical by 15.0% during the third quarter. Maryland State Retirement & Pension System now owns 11,002 shares of the biotechnology company’s stock valued at $660,000 after acquiring an additional 1,431 shares in the last quarter. Lisanti Capital Growth LLC acquired a new position in shares of BioMarin Pharmaceutical in the third quarter worth about $6,176,000. New York Life Investment Management LLC lifted its stake in shares of BioMarin Pharmaceutical by 14.4% in the third quarter. New York Life Investment Management LLC now owns 27,564 shares of the biotechnology company’s stock worth $1,654,000 after acquiring an additional 3,460 shares in the last quarter. M&G PLC lifted its stake in shares of BioMarin Pharmaceutical by 1.2% in the third quarter. M&G PLC now owns 218,723 shares of the biotechnology company’s stock worth $13,123,000 after acquiring an additional 2,627 shares in the last quarter. Finally, AlphaCore Capital LLC boosted its holdings in BioMarin Pharmaceutical by 73.9% in the third quarter. AlphaCore Capital LLC now owns 6,367 shares of the biotechnology company’s stock valued at $382,000 after purchasing an additional 2,706 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported Q3 revenue of $1.02 billion, up 32% year over year, and EPS of $0.23 versus analysts’ expected loss of $0.05. Revenue was in line with consensus, while earnings beat expectations. BioMarin Q3 2026 earnings call highlights
• Positive Sentiment: An analyst sees a more attractive risk-reward profile ahead of three FDA decisions. Potential expansion of Voxzogo into hypochondroplasia and revenue from the Amicus acquisition could support growth, though the acquisition’s debt burden remains a consideration. BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions
• Neutral Sentiment: JPMorgan lowered its price target to $86 from $87 but maintained an Overweight rating. HC Wainwright also reaffirmed its Neutral rating. JPMorgan analyst rating HC Wainwright rating
• Neutral Sentiment: Management plans to present at three November investor conferences; the announcement did not include new financial guidance. BioMarin investor conferences announcement
• Negative Sentiment: Royal Bank of Canada and Morgan Stanley lowered their expectations for BMRN, contributing to selling pressure and a gap lower in the shares following an analyst downgrade. RBC lowers expectations Morgan Stanley lowers expectations Shares gap down following analyst downgrade

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.